Recommendations for selecting drug-drug interactions for clinical decision support

Hugh Tilson, Lisa E. Hines, Gerald McEvoy, David M. Weinstein, Philip D. Hansten, Karl Matuszewski, Marianne Le Comte, Stefanie Higby-Baker, Joseph T. Hanlon, Lynn Pezzullo, Kathleen Vieson, Amy L. Helwig, Shiew Mei Huang, Anthony Perre, David W. Bates, John Poikonen, Michael A. Wittie, Amy J Jones-Grizzle, Mary Brown, Daniel C Malone

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose. Recommendations for including drug-drug interactions (DDIs) in clinical decision support (CDS) are presented. Summary. A conference series was conducted to improve CDS for DDIs. A work group consisting of 20 experts in pharmacology, drug information, and CDS from academia, government agencies, health information vendors, and healthcare organizations was convened to address (1) the process to use for developing and maintaining a standard set of DDIs, (2) the information that should be included in a knowledge base of standard DDIs, (3) whether a list of contraindicated drug pairs can or should be established, and (4) how to more intelligently filter DDI alerts. We recommend a transparent, systematic, and evidence-driven process with graded recommendations by a consensus panel of experts and oversight by a national organization. We outline key DDI information needed to help guide clinician decision-making. We recommend judicious classification of DDIs as contraindicated and more research to identify methods to safely reduce repetitive and less-relevant alerts. Conclusion. An expert panel with a centralized organizer or convener should be established to develop and maintain a standard set of DDIs for CDS in the United States. The process should be evidence driven, transparent, and systematic, with feedback from multiple stakeholders for continuous improvement. The scope of the expert panel's work should be carefully managed to ensure that the process is sustainable. Support for research to improve DDI alerting in the future is also needed. Adoption of these steps may lead to consistent and clinically relevant content for interruptive DDIs, thus reducing alert fatigue and improving patient safety.

Original languageEnglish (US)
Pages (from-to)576-585
Number of pages10
JournalAmerican Journal of Health-System Pharmacy
Volume73
Issue number8
DOIs
StatePublished - Apr 15 2016

Fingerprint

Clinical Decision Support Systems
Drug Interactions
Pharmaceutical Preparations
Organizations
Government Agencies
Knowledge Bases
Patient Safety
Research
Fatigue

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Recommendations for selecting drug-drug interactions for clinical decision support. / Tilson, Hugh; Hines, Lisa E.; McEvoy, Gerald; Weinstein, David M.; Hansten, Philip D.; Matuszewski, Karl; Le Comte, Marianne; Higby-Baker, Stefanie; Hanlon, Joseph T.; Pezzullo, Lynn; Vieson, Kathleen; Helwig, Amy L.; Huang, Shiew Mei; Perre, Anthony; Bates, David W.; Poikonen, John; Wittie, Michael A.; Jones-Grizzle, Amy J; Brown, Mary; Malone, Daniel C.

In: American Journal of Health-System Pharmacy, Vol. 73, No. 8, 15.04.2016, p. 576-585.

Research output: Contribution to journalArticle

Tilson, H, Hines, LE, McEvoy, G, Weinstein, DM, Hansten, PD, Matuszewski, K, Le Comte, M, Higby-Baker, S, Hanlon, JT, Pezzullo, L, Vieson, K, Helwig, AL, Huang, SM, Perre, A, Bates, DW, Poikonen, J, Wittie, MA, Jones-Grizzle, AJ, Brown, M & Malone, DC 2016, 'Recommendations for selecting drug-drug interactions for clinical decision support', American Journal of Health-System Pharmacy, vol. 73, no. 8, pp. 576-585. https://doi.org/10.2146/ajhp150565
Tilson H, Hines LE, McEvoy G, Weinstein DM, Hansten PD, Matuszewski K et al. Recommendations for selecting drug-drug interactions for clinical decision support. American Journal of Health-System Pharmacy. 2016 Apr 15;73(8):576-585. https://doi.org/10.2146/ajhp150565
Tilson, Hugh ; Hines, Lisa E. ; McEvoy, Gerald ; Weinstein, David M. ; Hansten, Philip D. ; Matuszewski, Karl ; Le Comte, Marianne ; Higby-Baker, Stefanie ; Hanlon, Joseph T. ; Pezzullo, Lynn ; Vieson, Kathleen ; Helwig, Amy L. ; Huang, Shiew Mei ; Perre, Anthony ; Bates, David W. ; Poikonen, John ; Wittie, Michael A. ; Jones-Grizzle, Amy J ; Brown, Mary ; Malone, Daniel C. / Recommendations for selecting drug-drug interactions for clinical decision support. In: American Journal of Health-System Pharmacy. 2016 ; Vol. 73, No. 8. pp. 576-585.
@article{d43b2053d91b478fb25a1e89d47e4bf1,
title = "Recommendations for selecting drug-drug interactions for clinical decision support",
abstract = "Purpose. Recommendations for including drug-drug interactions (DDIs) in clinical decision support (CDS) are presented. Summary. A conference series was conducted to improve CDS for DDIs. A work group consisting of 20 experts in pharmacology, drug information, and CDS from academia, government agencies, health information vendors, and healthcare organizations was convened to address (1) the process to use for developing and maintaining a standard set of DDIs, (2) the information that should be included in a knowledge base of standard DDIs, (3) whether a list of contraindicated drug pairs can or should be established, and (4) how to more intelligently filter DDI alerts. We recommend a transparent, systematic, and evidence-driven process with graded recommendations by a consensus panel of experts and oversight by a national organization. We outline key DDI information needed to help guide clinician decision-making. We recommend judicious classification of DDIs as contraindicated and more research to identify methods to safely reduce repetitive and less-relevant alerts. Conclusion. An expert panel with a centralized organizer or convener should be established to develop and maintain a standard set of DDIs for CDS in the United States. The process should be evidence driven, transparent, and systematic, with feedback from multiple stakeholders for continuous improvement. The scope of the expert panel's work should be carefully managed to ensure that the process is sustainable. Support for research to improve DDI alerting in the future is also needed. Adoption of these steps may lead to consistent and clinically relevant content for interruptive DDIs, thus reducing alert fatigue and improving patient safety.",
author = "Hugh Tilson and Hines, {Lisa E.} and Gerald McEvoy and Weinstein, {David M.} and Hansten, {Philip D.} and Karl Matuszewski and {Le Comte}, Marianne and Stefanie Higby-Baker and Hanlon, {Joseph T.} and Lynn Pezzullo and Kathleen Vieson and Helwig, {Amy L.} and Huang, {Shiew Mei} and Anthony Perre and Bates, {David W.} and John Poikonen and Wittie, {Michael A.} and Jones-Grizzle, {Amy J} and Mary Brown and Malone, {Daniel C}",
year = "2016",
month = "4",
day = "15",
doi = "10.2146/ajhp150565",
language = "English (US)",
volume = "73",
pages = "576--585",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "8",

}

TY - JOUR

T1 - Recommendations for selecting drug-drug interactions for clinical decision support

AU - Tilson, Hugh

AU - Hines, Lisa E.

AU - McEvoy, Gerald

AU - Weinstein, David M.

AU - Hansten, Philip D.

AU - Matuszewski, Karl

AU - Le Comte, Marianne

AU - Higby-Baker, Stefanie

AU - Hanlon, Joseph T.

AU - Pezzullo, Lynn

AU - Vieson, Kathleen

AU - Helwig, Amy L.

AU - Huang, Shiew Mei

AU - Perre, Anthony

AU - Bates, David W.

AU - Poikonen, John

AU - Wittie, Michael A.

AU - Jones-Grizzle, Amy J

AU - Brown, Mary

AU - Malone, Daniel C

PY - 2016/4/15

Y1 - 2016/4/15

N2 - Purpose. Recommendations for including drug-drug interactions (DDIs) in clinical decision support (CDS) are presented. Summary. A conference series was conducted to improve CDS for DDIs. A work group consisting of 20 experts in pharmacology, drug information, and CDS from academia, government agencies, health information vendors, and healthcare organizations was convened to address (1) the process to use for developing and maintaining a standard set of DDIs, (2) the information that should be included in a knowledge base of standard DDIs, (3) whether a list of contraindicated drug pairs can or should be established, and (4) how to more intelligently filter DDI alerts. We recommend a transparent, systematic, and evidence-driven process with graded recommendations by a consensus panel of experts and oversight by a national organization. We outline key DDI information needed to help guide clinician decision-making. We recommend judicious classification of DDIs as contraindicated and more research to identify methods to safely reduce repetitive and less-relevant alerts. Conclusion. An expert panel with a centralized organizer or convener should be established to develop and maintain a standard set of DDIs for CDS in the United States. The process should be evidence driven, transparent, and systematic, with feedback from multiple stakeholders for continuous improvement. The scope of the expert panel's work should be carefully managed to ensure that the process is sustainable. Support for research to improve DDI alerting in the future is also needed. Adoption of these steps may lead to consistent and clinically relevant content for interruptive DDIs, thus reducing alert fatigue and improving patient safety.

AB - Purpose. Recommendations for including drug-drug interactions (DDIs) in clinical decision support (CDS) are presented. Summary. A conference series was conducted to improve CDS for DDIs. A work group consisting of 20 experts in pharmacology, drug information, and CDS from academia, government agencies, health information vendors, and healthcare organizations was convened to address (1) the process to use for developing and maintaining a standard set of DDIs, (2) the information that should be included in a knowledge base of standard DDIs, (3) whether a list of contraindicated drug pairs can or should be established, and (4) how to more intelligently filter DDI alerts. We recommend a transparent, systematic, and evidence-driven process with graded recommendations by a consensus panel of experts and oversight by a national organization. We outline key DDI information needed to help guide clinician decision-making. We recommend judicious classification of DDIs as contraindicated and more research to identify methods to safely reduce repetitive and less-relevant alerts. Conclusion. An expert panel with a centralized organizer or convener should be established to develop and maintain a standard set of DDIs for CDS in the United States. The process should be evidence driven, transparent, and systematic, with feedback from multiple stakeholders for continuous improvement. The scope of the expert panel's work should be carefully managed to ensure that the process is sustainable. Support for research to improve DDI alerting in the future is also needed. Adoption of these steps may lead to consistent and clinically relevant content for interruptive DDIs, thus reducing alert fatigue and improving patient safety.

UR - http://www.scopus.com/inward/record.url?scp=84964026763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964026763&partnerID=8YFLogxK

U2 - 10.2146/ajhp150565

DO - 10.2146/ajhp150565

M3 - Article

C2 - 27045070

AN - SCOPUS:84964026763

VL - 73

SP - 576

EP - 585

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 8

ER -